Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Closer Look At The US Pricing Pushback

This article was originally published in Scrip

Executive Summary

Critics of high prescription drug prices are making headlines in the US, and politicians on the presidential campaign trail and on Capitol Hill are talking about government-imposed price controls. But the real news may be unfolding behind the scenes in the private health insurance market, as Cathy Kelly finds out.

You may also be interested in...



Cigna’s Bradbury Talks PCSK9 Contracts And Value Versus Volume

Amgen and Sanofi/Regeneron will pay deeper discounts if patients taking Repatha and Praluent don’t experience similar levels of LDL-cholesterol lowering as was seen in clinical trials.

Senate Insulin Bill Focuses On List Prices With Carrot For Manufacturers, Stick For PBMs

US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.

Back To The Well: Rebate Reform Rule Delay Would Fund Senate Gun Control Bill Provisions

For biopharma manufacturers, chipping away at the rebate rule is a relatively painless drug pricing “pay for” compared to price control policies.

Topics

Latest News
UsernamePublicRestriction

Register

SC063924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel